All
Medical errors reduced using electronic means
May 1st 2004Seattle - Reducing medical errors can be greatly facilitated by bringing state-of-the-art information technology into offices, clinics, pharmacies, and hospitals, according to Paul Tang, M.D. "The status quo is unacceptable," he said. "We can't manage the amount of paper we have now as healthcare professionals."
Derms tackle patients' quality-of-life issues with need for rosacea-specific instrument
May 1st 2004Washington - Investigators developing a rosacea-specific quality-of-life instrument (RosaQoL) have demonstrated its reliability and validity and have begun testing its responsiveness to changes in rosacea severity, said Suephy C. Chen, M.D., M.S., at the annual meeting of the American Academy of Dermatology.
Aggressive treatment wins battle of juvenile dermatomyositis
May 1st 2004Washington - Timely diagnosis of juvenile dermatomyositis is critical because early aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis that is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Hair loss in elderly may pack a potent psychological punch; evaluate carefully
May 1st 2004Washington - While hair loss may become more acceptable with increasing age, for some older people it is psychologically devastating and adds to the string of losses they may encounter, said Janet L. Roberts, M.D., at the annual meeting of the American Academy of Dermatology.
Botox has long duration of action for Tx of axillary hyperhidrosis
May 1st 2004Washington - Intradermal botulinum toxin type A (Botox) for the treatment of primary axillary hyperhidrosis produces a durable effect, with nearly half of patients requiring only one treatment over a one-year period, according to study data released at the annual meeting of the American Academy of Dermatology here.
Not all topical anesthetics are alike
May 1st 2004Waikoloa, Hawaii - The increase in the number of topical anesthesia options available mandates that dermatologists consider how they compare with respect to efficacy, safety, and patient convenience when selecting an agent to minimize the pain of a cutaneous procedure, said Dina N. Anderson, M.D., at the recent annual Hawaii Dermatology Seminar.
Antimicrobial dressingsretooled for the present
May 1st 2004Washington - The phrase "what is old is new again" aptly describes the current status of antimicrobial dressings, which, thanks to a new generation of products, are making a comeback in the woundcare arena, said Marketa Limova, M.D., at the annual meeting of the American Academy of Dermatology.
Long-term outcome of juvenile dermatomyositis rests on early treatment with immunosuppresants
May 1st 2004Washington -Timely diagnosis of juvenile dermatomyositis is critical because early, aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis, which is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Oral tazarotene shows sustained efficacy in psoriasis
May 1st 2004Washington - Oral tazarotene has sustained efficacy in the treatment of moderate to very severe plaque psoriasis with no cumulative toxicity. Alan Menter, M.D., presented data from a one-year, open-label study at the 62nd annual meeting of the American Academy of Dermatology.
Oral tazarotene delivers lasting results
May 1st 2004Washington -- Oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.,) gives patients with plaque psoriasis significant improvements that continue after treatment stops, according to a poster study presented at this year's annual meeting of the American Academy of Dermatology. The blinded, placebo-controlled, multicenter study of about 700 patients shows that oral tazarotene delivers several advantages over existing treatment alternatives.